Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)

China flag China · Delayed Price · Currency is CNY
5.78
-0.04 (-0.69%)
Apr 30, 2026, 12:54 PM CST
-2.03%
Market Cap 6.09B
Revenue (ttm) 1.04B
Net Income (ttm) 259.16M
Shares Out 1.05B
EPS (ttm) 0.25
PE Ratio 23.50
Forward PE n/a
Dividend 0.06 (1.05%)
Ex-Dividend Date Nov 27, 2025
Volume 4,989,680
Average Volume 12,956,258
Open 5.77
Previous Close 5.82
Day's Range 5.76 - 5.81
52-Week Range 5.59 - 7.03
Beta 0.39
RSI 40.59
Earnings Date Apr 28, 2026

About SHE:300039

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and respiratory infections; and Phlegm-Heat Clearing Capsules to clear heat, resolve phlegm, and detoxifying. It also provides liver-protecting products, ... [Read more]

Sector Healthcare
Founded 2000
Employees 1,225
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300039
Full Company Profile

Financial Performance

In 2025, SHE:300039's revenue was 1.15 billion, a decrease of -21.76% compared to the previous year's 1.47 billion. Earnings were 278.58 million, a decrease of -25.83%.

Financial Statements

News

There is no news available yet.